(August 31, 2017, 2:01 PM EDT) -- WASHINGTON, D.C. — A Delaware federal judge’s ruling, following a bench trial, that four patents covering thrice-weekly injections of 40 mg glatiramer acetate (GA) are invalid was erroneous, the makers of the drug recently told the Federal Circuit U.S. Court of Appeals (Teva Pharmaceuticals USA Inc., et al. v. Sandoz Inc., et al., No. 17-1575, Fed. Cir.)....